{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:00Z","timestamp":1793665980474,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current study aimed to address whether ripasudil, a Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor developed to treat glaucoma and ocular hypertension (OH), improves diabetic macular edema (DME) since it is known that ROCK upregulates vascular endothelial growth factor. We retrospectively investigated the foveal thickness (FT) measured by spectral-domain optical coherence tomography, visual acuity (VA), and intraocular pressure (IOP) in 12 eyes with DME that received ripasudil treatment for primary open-angle glaucoma or OH and compared them with 14 eyes that received no treatment. One month after ripasudil therapy, the mean FT decreased significantly from 439\u2009\u00b1\u200972\u2009\u00b5m to 395\u2009\u00b1\u200962\u2009\u00b5m (<jats:italic>P<\/jats:italic>\u2009=\u20090.003); this change was significantly different from that in the controls, in which the mean FT increased by 1\u2009\u00b1\u200939\u2009\u00b5m (<jats:italic>P<\/jats:italic>\u2009=\u20090.01). Ripasudil also caused a significant decrease in IOP from 17.3\u2009\u00b1\u20095.2\u2009mmHg to 14.6\u2009\u00b1\u20094.0\u2009mmHg (<jats:italic>P<\/jats:italic>\u2009=\u20090.02); this change was significantly greater than that in the controls, in which IOP changed by 0.0\u2009\u00b1\u20091.6\u2009mmHg (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.008). There was no significant difference in the VA changes between groups. Our results suggested that ripasudil may have positive effects on both IOP and DME.<\/jats:p>","DOI":"10.1038\/s41598-019-40194-5","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T11:07:05Z","timestamp":1551870425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effect of ripasudil on diabetic macular edema"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6252-8036","authenticated-orcid":false,"given":"Yoshiro","family":"Minami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-seok","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ishibazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneaki","family":"Omae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ro-mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2123-4055","authenticated-orcid":false,"given":"Satoshi","family":"ishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"40194_CR1","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","volume":"26","author":"TA Ciulla","year":"2003","unstructured":"Ciulla, T. A., Amador, A. G. & Zinman, B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 26, 2653\u20132664 (2003).","journal-title":"Diabetes Care."},{"key":"40194_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau, J. W. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35, 556\u2013564 (2012).","journal-title":"Diabetes Care."},{"key":"40194_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","volume":"103","author":"S Fogli","year":"2016","unstructured":"Fogli, S., Mogavero, S., Egan, C. G., Del Re, M. & Danesi, R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 103, 149\u2013157 (2016).","journal-title":"Pharmacol Res."},{"key":"40194_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell, P. et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 118, 615\u2013625, https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.031 (2011).","journal-title":"Ophthalmology."},{"key":"40194_CR5","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","volume":"119","author":"MJ Elman","year":"2012","unstructured":"Elman, M. J. et al. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 119, 2312\u20132318, https:\/\/doi.org\/10.1016\/j.ophtha.2012.08.022 (2012).","journal-title":"Ophthalmology."},{"key":"40194_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","volume":"122","author":"T Ishibashi","year":"2015","unstructured":"Ishibashi, T. et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 122, 1402\u20131415, https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.006 (2015).","journal-title":"Ophthalmology."},{"key":"40194_CR7","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown, D. M., Schmidt-Erfurth, U. & Do, D. V. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID Studies. Ophthalmology. 122, 2044\u20132052, https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.017 (2015).","journal-title":"Ophthalmology."},{"key":"40194_CR8","doi-asserted-by":"publisher","unstructured":"Nguyen Q. D. et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 789\u2013801 https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039. Epub 2012 Feb 11 (2012).","DOI":"10.1016\/j.ophtha.2011.12.039."},{"key":"40194_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones, K. P. Ripasudil: first global approval. Drugs. 74, 2211\u20132215 (2014).","journal-title":"Drugs."},{"key":"40194_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe, T. et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 39, 813\u2013822 (2014).","journal-title":"Curr Eye Res."},{"key":"40194_CR11","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara, H. et al. The K-115 Clinical Study Group. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 93, e254\u2013e260 (2015).","journal-title":"Acta Ophthalmol."},{"key":"40194_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10384-007-0471-0","volume":"51","author":"T Yokota","year":"2007","unstructured":"Yokota, T. et al. Involvement of the Rho\/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol. 51, 424\u2013430 (2007).","journal-title":"Jpn J Ophthalmol."},{"key":"40194_CR13","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1167\/iovs.12-10757","volume":"54","author":"R Arita","year":"2013","unstructured":"Arita, R. et al. A key role for ROCK in TNF-alpha-mediated diabetic microvascular damage. Invest Ophthalmol Vis Sci. 54, 2373\u20132383, https:\/\/doi.org\/10.1167\/iovs.12-10757 (2013).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"40194_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2337\/db08-0762","volume":"58","author":"R Arita","year":"2009","unstructured":"Arita, R. et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes. 58, 215\u2013226, https:\/\/doi.org\/10.2337\/db08-0762 (2009).","journal-title":"Diabetes."},{"key":"40194_CR15","first-page":"337","volume":"8","author":"R Nourinia","year":"2013","unstructured":"Nourinia, R. et al. Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. J Ophthalmic Vis Res. 8, 337\u2013340 (2013).","journal-title":"J Ophthalmic Vis Res."},{"key":"40194_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaophthalmol.2013.143","volume":"131","author":"H Ahmadieh","year":"2013","unstructured":"Ahmadieh, H., Nourinia, R. & Hafezi-Moghadam, A. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment. JAMA Ophthalmology. 131, 923\u2013924, https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.143 (2013).","journal-title":"JAMA Ophthalmology."},{"key":"40194_CR17","doi-asserted-by":"crossref","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology. 98, 807\u2013822(1991).","DOI":"10.1016\/S0161-6420(13)38013-0"},{"key":"40194_CR18","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo, M. et al. Effects of rho\u2010associated protein kinase inhibitor Y\u201027632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 42, 137\u2013144 (2001).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"40194_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3109\/02713683.2011.593110","volume":"36","author":"X Fang","year":"2011","unstructured":"Fang, X., Ueno, M., Yamashita, T. & Ikuno, Y. RhoA activation and effect of Rho-kinase inhibitor in the development of retinal neovascularization in a mouse model of oxygen-induced retinopathy. Curr Eye Res. 36, 1028\u20131036, https:\/\/doi.org\/10.3109\/02713683.2011.593110 (2011).","journal-title":"Curr Eye Res."},{"key":"40194_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10384-007-0487-5","volume":"52","author":"Y Hata","year":"2008","unstructured":"Hata, Y. et al. Antiangiogenic properties of fasudil, a potent Rho-kinase inhibitor. Jpn J Ophthalmol. 52, 16\u201323, https:\/\/doi.org\/10.1007\/s10384-007-0487-5 (2008).","journal-title":"Jpn J Ophthalmol."},{"key":"40194_CR21","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1167\/iovs.15-17411","volume":"57","author":"M Yamaguchi","year":"2016","unstructured":"Yamaguchi, M. et al. Vascular normalization by ROCK inhibitor: therapeutic potential of ripasudil (K-115) eye drop in retinal angiogenesis and hypoxia. Invest Ophthalmol Vis Sci. 57, 2264\u20132276, https:\/\/doi.org\/10.1167\/iovs.15-17411 (2016).","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"40194_CR22","doi-asserted-by":"publisher","unstructured":"Hollanders K. et al. 4. AMA0428, a potent rock inhibitor, attenuates early and late experimental diabetic retinopathy. Curr Eye Res. 42, 260\u2013272, https:\/\/doi.org\/10.1080\/02713683.2016.1183030. Epub 2016 Jul 11 (2017).","DOI":"10.1080\/02713683.2016.1183030."},{"key":"40194_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07329-y","volume":"7","author":"PR Rothschild","year":"2017","unstructured":"Rothschild, P. R. et al. ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy. Sci Rep. 7, 8834 https:\/\/www.nature.com\/articles\/s41598-017-07329-y (2017).","journal-title":"Sci Rep."},{"key":"40194_CR24","doi-asserted-by":"publisher","unstructured":"Yamaguchi M. et al. Rho-Kinase\/ROCK as a potential drug target for vitreoretinal diseases. J Ophthalmol. 2017, :8543592, https:\/\/doi.org\/10.1155\/2017\/8543592. Epub 2017 May 10. Review (2017).","DOI":"10.1155\/2017\/8543592."},{"key":"40194_CR25","doi-asserted-by":"publisher","unstructured":"Hida Y et al. Effects of ripasudil, a ROCK inhibitor, on retinal edema and nonperfusion area in a retinal vein occlusion murine model. J Pharmacol Sci. 137, 129\u2013136, https:\/\/doi.org\/10.1016\/j.jphs.2018.06.010. Epub 2018 Jun 19 (2018).","DOI":"10.1016\/j.jphs.2018.06.010."},{"key":"40194_CR26","doi-asserted-by":"publisher","unstructured":"Isobe T., Kasai T. & Kawai H. Ocular penetration and pharmacokinetics of ripasudil following topical administration to rabbits. J Ocul Pharmacol Ther. 32, 405\u2013414, https:\/\/doi.org\/10.1089\/jop.2016.0028. Epub 2016 Jul 27 (2016).","DOI":"10.1089\/jop.2016.0028."},{"key":"40194_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross, E. L. et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 134, 888\u201396, https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.1669 (2016).","journal-title":"JAMA Ophthalmol."},{"key":"40194_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"RL Avery","year":"2016","unstructured":"Avery, R. L. & Gordon, G. M. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 134, 21\u201329, https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4070 (2016).","journal-title":"JAMA Ophthalmol."},{"key":"40194_CR29","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030.","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro, P. A. et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 119, 2125\u20132132, https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.030. Epub 2012 Jun 21 (2012).","journal-title":"Ophthalmology."},{"key":"40194_CR30","doi-asserted-by":"crossref","unstructured":"Browning D. J. et al. Diabetic Retinopathy Clinical Research Network, Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 114, 525\u2013536 Epub 2006 Nov 21 (2007).","DOI":"10.1016\/j.ophtha.2006.06.052"},{"key":"40194_CR31","doi-asserted-by":"publisher","unstructured":"Matsuda S. et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 28, 166\u2013170, https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.11.009. Epub 2013 Nov 27 (2014).","DOI":"10.1016\/j.jdiacomp.2013.11.009."},{"key":"40194_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","volume":"38","author":"AR Santos","year":"2018","unstructured":"Santos, A. R. et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: The Chartres Study. Retina. 38, 1110\u20131119, https:\/\/doi.org\/10.1097\/IAE.0000000000001687 (2018).","journal-title":"Retina."},{"key":"40194_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/IAE.0000000000001626","volume":"38","author":"W Fickweiler","year":"2018","unstructured":"Fickweiler, W. et al. Predictive value of optical coherence tomographic features in the Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME) Study. Retina. 38, 812\u2013819, https:\/\/doi.org\/10.1097\/IAE.0000000000001626 (2018).","journal-title":"Retina."},{"key":"40194_CR34","doi-asserted-by":"publisher","unstructured":"Kang J. W., Chung H. & Chan Kim H. Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema. Retina. 1630\u20131639, https:\/\/doi.org\/10.1097\/IAE.0000000000000995 (2016).","DOI":"10.1097\/IAE.0000000000000995"},{"key":"40194_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","volume":"33","author":"M Shimura","year":"2013","unstructured":"Shimura, M., Yasuda, K., Yasuda, M. & Nakazawa, T. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina. 33, 740\u2013747, https:\/\/doi.org\/10.1097\/IAE.0b013e31826b6763 (2013).","journal-title":"Retina."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40194-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:08:10Z","timestamp":1671260890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40194-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40194"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40194-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3703"}}